Please ensure Javascript is enabled for purposes of website accessibility

Here's Why AstraZeneca Plc's Market Value Rose $3.8 Billion in February

By Cory Renauer - Mar 6, 2017 at 1:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With generic competition choking its largest revenue streams, investors still found some reasons to smile.

What happened

American depositary receipts (ADRs) for AstraZeneca plc (AZN -0.18%) notched a 5.4% gain in February, while the big pharma's London-traded shares tacked on 9.4%, according to data from S&P Global Market Intelligence. Despite sliding sales in the face of generic competition, AstraZeneca's oncology programs gave investors reason to smile. 

So what 

Last year, sales of AstraZeneca's top three drugs sank by double-digit percentages, but it might not be time to jump ship just yet. In its first full year post-approval, lung cancer treatment Tagrisso added an impressive $423 million to the top line.

Woman looking up in front of upward sloping arrows drawn on a chalkboard

Image source: Getty Images.

A successful new launch is especially encouraging, considering a few of the most promising new entities in late-stage development across the industry belong to AstraZeneca. By 2022, oncology candidates durvalumab, tremelimumab, and acalabrutinib are expected to generate $2.3 billion, $1.3 billion, and $968 million, respectively.

Later in the month, the company presented positive late-stage trial data for Lynparza that could help it become the first PARP inhibitor available for the treatment of breast cancer. This one of the most-watched new classes of oral cancer treatments, and an expansion to the much larger indication could help the drug generate about $2 billion in sales each year.

Now what

Although peak estimates for a handful drugs in AstraZeneca's late-stage pipeline suggest they could offset losses to generic competition, there's plenty that could go wrong. The Food and Drug Administration is currently mulling durvalumab's application for the treatment of bladder cancer, but Roche's drug of the same class is already becoming entrenched in that population. There's also a deep concern a combination of durvalumab and tremelimumab might flop in a lung cancer trial after Bristol-Myers Squibb scuttled a similar trial with two drugs of the same classes.

AstraZeneca's future hinges on its late-stage oncology pipeline. Until its future is less uncertain, it's probably best to watch from a safe distance.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
$65.95 (-0.18%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.